A Phase 2 interventional study of Lopinavir/Ritonavir and Efavirenz in HIV Infections, sponsored by ViRx. Completed at 1 site in United States. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by ViRx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies testing efavirenz in HIV Infections — none open to participants now, none under way, none of them phase 3. efavirenz · HIV Infections.
Among the 101 studies testing efavirenz in HIV Infections, this one is one of 22 in phase 2, and was the 1st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 101 studies testing efavirenz in HIV Infections is open now. The open studies under HIV Infections, anywhere →
efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 24 · Phase 3 28 · Phase 4 28
First in 1997; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 75 across the 96 interventional studies. Of the 91 that completed or were terminated, 18 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 101 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with ViRx as lead sponsor.
ViRx has 1 study filed under HIV Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 101 studies testing efavirenz in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).
All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study. Patients take study medications for 48 weeks, during which time there will be 15 study visits. There is a possibility of a study extension after 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients may be eligible for this study if they:
Exclusion Criteria
Patients will not be eligible for this study if they:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Aug 2000. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efavirenz